Abbreviations and acronyms

aDSM

active TB drug-safety monitoring and management

AFB

acid-fast bacilli

AIDS

acquired immunodeficiency syndrome

aIPD

adult individual patient data

aOR

adjusted odds ratio

aRR

adjusted risk ratio

ART

antiretroviral therapy

BMI

body mass index

BPaL

bedaquiline, pretomanid and linezolid

BPaLC

bedaquiline, pretomanid, linezolid and clofazimine

BPaLM

bedaquiline, pretomanid, linezolid and moxifloxacin

CI

confidence interval

CL

confidence limits

CNS

central nervous system

DELIBERATE

DELamanId Bedaquiline for ResistAnt TubErculosis (trial)

DR-TB

drug-resistant tuberculosis

DST

drug susceptibility testing

ECG

electrocardiogram

EDRWeb

Electronic Drug-Resistant Tuberculosis Register (South Africa)

FDC

fixed-dose combination (medicines)

GDF

Global Drug Facility

GDG

Guideline Development Group

GRADE

Grading of Recommendations Assessment, Development and Evaluation

HIV

human immunodeficiency virus

HR

isoniazid–rifampicin

HREZ

isoniazid–rifampicin–ethambutol–pyrazinamide

(H)REZ

(isoniazid optional)–rifampicin–ethambutol–pyrazinamide

Hr-TB

rifampicin-susceptible, isoniazid-resistant tuberculosis

IPD

individual patient data (or dataset)

IQR

interquartile range

LPA

line probe assay

M. tuberculosis

Mycobacterium tuberculosis

MDR-TB

multidrug-resistant tuberculosis

MDR/RR-TB

multidrug- or rifampicin-resistant tuberculosis

MIC

minimum inhibitory concentration

MSF

Médecins Sans Frontières

NExT

Newer and Emerging Treatment for MDR/RR-TB (trial)

NTP

national TB programme

PICO

population, intervention, comparator and outcomes

People with HIV

people living with HIV

pre-XDR-TB

pre-extensively drug-resistant tuberculosis

QTcF

corrected QT interval by Fredericia

RCT

randomized controlled trial

RD

risk difference

REZ

rifampicin–ethambutol–pyrazinamide

RR

risk ratio

RR-TB

rifampicin-resistant tuberculosis

SAT

self-administered therapy (also meaning unsupervised treatment)

SRL

TB Supranational Reference Laboratory

STREAM

Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients with MDR-TB (trial)

TB

tuberculosis

US CDC

United States Centers for Disease Control and Prevention

USA

United States of America

WHO

World Health Organization

WHO/GTB

Global Tuberculosis Programme of the World Health Organization

XDR-TB

extensively drug-resistant tuberculosis

TB medicines

B or Bdq

bedaquiline

C or Cfz

clofazimine

Cs

cycloserine

Dlm

delamanid

E

ethambutol

Eto

ethionamide

FQ

fluoroquinolones

H

isoniazid

Hh

isoniazid high dose

Ipm-Cln

imipenem–cilastatin

L or Lzd

linezolid

Lfx

levofloxacin

M or Mfx

moxifloxacin

Mpm

meropenem

P or Rpt

rifapentine

Pa

pretomanid

PAS

P-aminosalicylic acid

Pto

prothionamide

R

rifampicin

Z

pyrazinamide

Book navigation